Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy | MicrobiomeTrials
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2023-11-21Est. Completion: 2029-12-26
Enrollment target: 600 participants
Locations
Byers Eye Institute at Stanford University, Palo Alto, California, United States
Retina Consultants, Manchester, Connecticut, United States
Retina Associates of Florida, LLC, Tampa, Florida, United States
Emory Eye Center, Atlanta, Georgia, United States
Northwestern Memorial Group, Chicago, Illinois, United States
IL Eye and Ear Infirmary-University of Illinois at Chicago, Chicago, Illinois, United States
Midwest Eye Institute, Indianapolis, Indiana, United States
University of Iowa Department of Ophthalmology and Visual Sciences, Iowa City, Iowa, United States
University of Kentucky Advanced Eye Care, Lexington, Kentucky, United States
Massachusetts Eye and Ear, Boston, Massachusetts, United States
Foundation for Vision Research and Retina Specialists of Michigan, P.C., Grand Rapids, Michigan, United States
Associated Retinal Consultants, P.C., Royal Oak, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
Washington University Ophthalmology, St Louis, Missouri, United States
Retina Research Institute, LLC, St Louis, Missouri, United States
Other microbiome trials you might be interested in